EGFR抑制剂在非小细胞肺癌中的应用

Application of EGFR-TKI in non-small cell lung cancer

人类表皮生长因子受体(EGFR)是原癌基因C-erb B1的表达产物,属于酪氨酸激酶生长因子受体家族成员之一,在人类多种实体肿瘤中过度表达,与肿瘤细胞的增殖、侵袭、转移及血管生长等有关。选择EGFR为靶点是近年来非小细胞肺癌(NSCLC)治疗的前沿手段,第一代表皮生长因子受体酪氨酸激酶抑制剂(EGFR-TKIs)吉非替尼或厄洛替尼对于复发或进展期NSCLC显示出较好的疗效,但仅对特定人群有效。如何规范临床应用、建立完善的疗效预测系统、探讨耐药的机制及处理策略等是临床面临的难题。本文就关于这些问题的研究进展作一综述。

Epidermal growth factor receptor （EGFR） is the product of oncogene C-erbB1 and belongs to the tyrosine kinase growth factor receptor family. EGFR is overexpressed in many solid tumors, which can promote the proliferation, invading, metastasis, angiogenesis of tumor. The targeting therapy on EGFR has become the focus of clinical trials for the treatment of non-small cell lung cancer （NSCLC） and the first generation of EGFR-TKI gefitinib or erlotinib has showed a significant activity in the treatment of advanced or recurrent NSCLC, but either of them is effective only to the specific individuals. How to regulate clinical application, establish a thorough therapeutic effect evaluation system, explore the mechanism of resistance and treatment strategies have become clinical problems. This article summarizes the progress of studies on these problems.